Jesús Berdeja, MD, has worked at the Sarah Cannon Research Institute since 2008 where he currently serves as the Director of Myeloma Research. Dr Berdeja is also an associate of Tennessee Oncology, TN, US.
Dr Berdeja received his undergraduate degree from Stanford University, Stanford, CA, in 1990 and then went on to complete his medical degree in 1994 at Harvard Medical School, Boston, MA. He then went on to complete his internship and residency at the Department of Internal Medicine at the University of California in San Francisco, San Francisco, CA. Dr Berdeja also completed fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine, Baltimore, MD, and is board certified in internal medicine, medical oncology and hematology.
Speaking on novel therapies for hematological malignancies
Dr Berdeja specializes in the treatment of all hematological malignancies and in blood and marrow transplantation. Dr Berdeja is the lead clinical investigator on a number of clinical trials including those investigating novel chimeric antigen receptor (CAR) T-cell therapies and antibody-based therapies for the treatment of multiple myeloma.